{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:49:55Z","timestamp":1768880995992,"version":"3.49.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1097\/inf.0b013e3181e82608","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T09:49:02Z","timestamp":1277200142000},"page":"1072-1076","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics and Tolerability of Single-dose Intravenous Ertapenem in Infants, Children, and Adolescents"],"prefix":"10.1097","volume":"29","author":[{"given":"Susan M.","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory L.","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Topelberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goutam C.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chester J.","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Groff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Blumer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-4-20210202","first-page":"7","article-title":"Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties.","volume":"53","author":"Hammond","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R2-4-20210202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jac\/dkg375","article-title":"Properties and potential of ertapenem.","volume":"52","author":"Livermore","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"R3-4-20210202","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/AAC.41.8.1830","article-title":"Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.","volume":"41","author":"Jacoby","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-4-20210202","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/43.5.703","article-title":"In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.","volume":"43","author":"Fuchs","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"R5-4-20210202","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.45.10.2831-2837.2001","article-title":"Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-4-20210202","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.42.9.2365","article-title":"In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.","volume":"42","author":"Odenholt","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-4-20210202","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1086\/340348","article-title":"Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.","volume":"34","author":"Graham","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R8-4-20210202","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-8579(02)00160-7","article-title":"Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.","volume":"20","author":"Yellin","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"R9-4-20210202","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.SLA.0000048551.32606.73","article-title":"Ertapenem versus piperacillin\/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.","volume":"237","author":"Solomkin","year":"2003","journal-title":"Ann Surg"},{"issue":"suppl 2","key":"R10-4-20210202","first-page":"67","article-title":"Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.","volume":"53","author":"Wells","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R11-4-20210202","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0149-2918(02)80078-9","article-title":"A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.","volume":"24","author":"Vetter","year":"2002","journal-title":"Clin Ther"},{"key":"R12-4-20210202","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/339543","article-title":"A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.","volume":"34","author":"Ortiz-Ruiz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R14-4-20210202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijantimicag.2008.08.005","article-title":"Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infections, community acquired pneumonia, or skin and soft tissue infections.","volume":"33","author":"Arguedas","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"R16-4-20210202","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.amjsurg.2007.01.023","article-title":"Ertapenem or ticarcillin\/clavulanate for treatment of intra-abdominal infections or acute pelvic infections in pediatric patients.","volume":"194","author":"Yellin","year":"2007","journal-title":"Am J Surg"},{"key":"R17-4-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1570-0232(02)00240-4","article-title":"Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma.","volume":"783","author":"Musson","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R18-4-20210202","first-page":"M100","article-title":"Performance Standards for Antimicrobial Susceptibility Testing. Sixteenth Informational Supplement (S16).","year":"2006"},{"key":"R19-4-20210202","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1128\/AAC.46.11.3506-3511.2002","article-title":"Pharmacokinetics of ertapenem in healthy young volunteers.","volume":"46","author":"Majumdar","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-4-20210202","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology: the impact of ontogeny on drug disposition and action.","volume":"349","author":"Kearns","year":"2003","journal-title":"New Engl J Med"},{"key":"R21-4-20210202","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1128\/AAC.46.9.2990-2995.2002","article-title":"Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model.","volume":"46","author":"Xuan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-4-20210202","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1128\/AAC.49.1.276-280.2005","article-title":"Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model.","volume":"49","author":"Maglio","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006454-201012000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:57:54Z","timestamp":1618034274000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201012000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e3181e82608","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}